Zymeworks Updates Annual Financial Targets After Finalizing Theravance Biopharma Deal
Zymeworks Inc. (NASDAQ: ZYME ) on Monday finalized its acquisition of Theravance Biopharma, releasing final transaction details and updated financial guidance for fiscal year 2026. The biotechnology company projects 2026 revenue between $278 million and $292 million, alongside 2026 adjusted EBITDA ranging from $114 mil